Anticholinesterase activity of plastoquinones from Sargassum sagamianum: lead compounds for alzheimer's disease therapy

During the search for anticholinesterase compounds from marine organisms, two known plastoquinones, sargaquinoic acid (1) and sargachromenol (2), were isolated from Sargassum sagamianum. Both compounds showed moderate acetylcholinesterase (AChE) inhibitory activity in a micromole range (IC50 23.2 and 32.7 µm, respectively). However, for butyrylcholinesterase (BuChE), a new target for the treatment of Alzheimer's disease (AD), compound 1 showed particularly potent inhibitory activity (IC50 26 nm), which is 1000‐fold greater than for AChE. Hence, sargaquinoic acid represents an effective and selective inhibitor of BuChE with a potency similar to or greater than the anticholinesterases in current clinical use, making it an interesting potential drug candidate for AD. Copyright © 2007 John Wiley & Sons, Ltd.

[1]  B. Choi,et al.  Cholinesterase inhibitory activity of two farnesylacetone derivatives from the brown algaSargassum sagamianum , 2003, Archives of pharmacal research.

[2]  H. Shirahama,et al.  New Plastoquinones from the Brown Alga Sargassum sagamianum var. yezoense , 1987 .

[3]  M. Ojika,et al.  Two new farnesylacetone derivatives from the brown alga Sargassum micracanthum , 1982 .

[4]  K. Courtney,et al.  A new and rapid colorimetric determination of acetylcholinesterase activity. , 1961, Biochemical pharmacology.

[5]  Sarka Stepankova and Karel Komers.  Cholinesterases and Cholinesterase Inhibitors , 2008 .

[6]  N. Greig,et al.  Rationale for the development of cholinesterase inhibitors as anti-Alzheimer agents. , 2004, Current pharmaceutical design.

[7]  N. Greig,et al.  Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent , 2005 .

[8]  N. Greig,et al.  Novel Anticholinesterases Based on the Molecular Skeletons of Furobenzofuran and Methanobenzodioxepine , 2005 .

[9]  D. Selkoe,et al.  Defining molecular targets to prevent Alzheimer disease. , 2005, Archives of neurology.

[10]  S. Nakazawa,et al.  Structure and Absolute Configuration of Sargatriol, a New Isoprenoid Chromenol from a Brown Alga, Sargassum tortile C. AGARDH , 1983 .

[11]  N. Greig,et al.  An overview of phenserine tartrate, a novel acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. , 2005, Current Alzheimer research.

[12]  T. Kusumi,et al.  New geranylgeranylbenzoquinone derivatives from Sargassum tortile. , 1979 .

[13]  C. Geula,et al.  Neurobiology of butyrylcholinesterase , 2003, Nature Reviews Neuroscience.

[14]  D. Drachman,et al.  Human memory and the cholinergic system. A relationship to aging? , 1974, Archives of neurology.

[15]  T. Kusumi,et al.  Structures of new plastoquinones from the brown alga Sargassum serratifolium , 1979 .

[16]  J. Becker,et al.  Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition , 2005, Journal of the American Geriatrics Society.

[17]  J. Raftery,et al.  Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial , 2004, The Lancet.

[18]  J. Kirsch,et al.  Fractional diffusion-limited component of reactions catalyzed by acetylcholinesterase. , 1986, Biochemistry.

[19]  Xiaoxiang Zhu,et al.  A New Therapeutic Target in Alzheimer's Disease Treatment: Attention to Butyrylcholinesterase , 2001, Current medical research and opinion.

[20]  A. Brossi,et al.  Alfred Burger award address. Bioactive alkaloids. 4. Results of recent investigations with colchicine and physostigmine. , 1990, Journal of medicinal chemistry.

[21]  N. Greig,et al.  A partial failure of membrane protein turnover may cause Alzheimer's disease: a new hypothesis. , 2006, Current Alzheimer research.

[22]  P. Ferry,et al.  Nutritional Status and Well Being. Is There a Relationship Between Body Mass Index and the Well-being of Older People? , 2001 .

[23]  Nigel H. Greig,et al.  Advances in the cellular and molecular biology of the beta-amyloid protein in Alzheimer’s disease , 2002, NeuroMolecular Medicine.

[24]  N. Greig,et al.  Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease. , 1999, Journal of medicinal chemistry.

[25]  Jia-sen Liu,et al.  The structures of huperzine A and B, two new alkaloids exhibiting marked anticholinesterase activity , 1986 .

[26]  KusumiTakenori,et al.  New farnesylacetone derivatives from Sargassum micracanthum. , 1979 .

[27]  N. Greig,et al.  Phenserine and ring C hetero‐analogues: Drug candidates for the treatment of Alzheimer's disease , 1995, Medicinal research reviews.

[28]  J. Cummings,et al.  Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.